A Novel Management to Severe Hypoattenuation Leaflet Thickening Following Transcatheter Aortic Valve Replacement
{{output}}
•First reported tissue plasminogen activator use to treat hypoattenuated leaflet thickening (HALT) post-transcatheter aortic valve replacement unresponsive to standard therapy.•Low-dose thrombolysis over 48 hours restored valve function.•Complete HALT resol... ...
